Navigation Links
Alternative to Warfarin May Cut Risk of Bleeding
Date:11/15/2009

Dabigatran etexilate does well in trial of atrial fibrillation patients

SUNDAY, Nov. 15 (HealthDay News) -- The anti-clotting drug dabigatran etexilate (Pradaxa) may be more effective and safer than warfarin at preventing clots and stroke in patients with atrial fibrillation, a new Swedish study has found.

Warfarin is effective in preventing blood clots that can cause stroke in patients with atrial fibrillation (abnormal heart rhythm) and other diseases, but the drug has a narrow therapeutic range in which it prevents strokes but doesn't cause bleeding, according to the researchers. This means that effective warfarin treatment requires regular laboratory monitoring to ensure warfarin levels remain in the range that lowers the risk of stroke without increasing the risk of bleeding.

This study included 18,113 atrial fibrillation patients in 44 countries who were randomly selected to receive either oral treatment with standard warfarin (6,022 patients) or dabigatran etexilate at either 110 milligrams (6,015 patients) or 150 milligrams (6,076 patients).

After one to three years of follow-up, 1.69 percent of patients in the warfarin group suffered a stroke or serious clot per year, compared with 1.53 percent and 1.11 percent of patients taking 110-milligram and 150-milligram doses of dabigatran etexilate, respectively, the study authors, from University Hospital in Uppsala, found.

Rates per year of major bleeding were 3.36 percent in the warfarin group and 2.71 percent and 3.11 percent for patients taking 110-milligram and 150-milligram doses of dabigatran etexilate, respectively.

The study was scheduled to be presented Sunday at the American Heart Association's annual meeting in Orlando, Fla.

The patients in the study were an average age of 72 and included some who'd suffered a prior stroke (13 percent), patients with high blood pressure (79 percent), those who'd never taken an oral anti-clotting drug for more than two months (50.4 percent), and those who weren't using an oral anti-clotting drug when they enrolled in the study (34 percent).

Dabigatran etexilate is approved for use in Canada and Europe but not in the United States.

More information

The American Academy of Family Physicians has more about atrial fibrillation.



-- Robert Preidt



SOURCE: American Heart Association, news release, Nov. 15, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) as Alternative to Drug- Eluting Stents
2. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
3. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
4. Trade-offs reveal no clear favorites in alternative energy market
5. Clinical trials present better alternatives for dialysis patients
6. New Technology at Unitrin Direct Gives Customers an Alternative to Waiting
7. Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration
8. Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008
9. After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative
10. Nosefrida Nasal Aspirator - A Parents Alternative to Medicines on the Verge of FDA Ban
11. Paramedics can provide an effective alternative to standard ambulance service in the community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/18/2017)... ... July 18, 2017 , ... ClinicalTrials.gov and the New ... Need to Consider?, **An FDAnews Webinar**, Aug. 2, 2017 — 1:30 p.m. – ... Rule for Clinical Trials Registration and Results Information,” is a head-scratcher. After reading ...
(Date:7/18/2017)... , ... July 18, 2017 , ... Heritage Woods of ... 11 a.m. to 12:30 p.m. on Aug. 15. , The community, which is located ... those on Medicaid, who need some help to maintain their independence. , The lunch ...
(Date:7/17/2017)... ... July 17, 2017 , ... McGraw Family Pledges $3 Million for New ... Generation of Healthcare Clinicians , NORWALK, Connecticut – July 17, 2017 – The ... investing in community health by pledging up to $3 million in a challenge gift ...
(Date:7/17/2017)... Louis, MO (PRWEB) , ... July 17, 2017 ... ... and higher education recruitment firm, recently completed a nationwide executive search for Springfield ... aggressive timeline, Springfield Clinic named Ray Williams, a skilled healthcare executive with more ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Wolfmet 3D  printed tungsten collimator manufactured by M&I Materials proves to ... progress molecular radiotherapy imaging. In molecular radiotherapy (MRT) ... quantify the radiation absorbed by those patients undergoing treatment. As ... radiotherapy treatment has been available — that is, until now. ... ...
(Date:7/5/2017)... of over 2,000 employees and a leader in environmental and life science testing, ... position as the top American owned and operated environmental testing firm in ... ... The ... , enhances Pace Analytical,s capability as an innovative full service provider in the ...
(Date:7/1/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... will be broadcast live over the Internet on Thursday, July ... detailing the quarterly results will be made available at 7:30 ... The live audio webcast can be accessed via Zimmer ... be archived for replay following the conference call. ...
Breaking Medicine Technology: